We identified 487 patients with a diagnosis of AML, sAML (from MDS), MDS, CMML, or MPN who had a U2AF1 mutation based on available sequencing data and calculated the proportion of patients with U2AF1R156/Q157 or U2AF1S34 mutations (see Supplementary Methods). Here, U2AF1 is linked to myeloproliferative disorder.